12 Month Price Forecast For ANL
Distance to ANL Price Forecasts
ANL Price Momentum
🤔 Considering Adlai Nortye (ANL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 10, 2025 2:34 PM UTC
ANL Analyst Ratings & Price Targets
Based on our analysis of 2 Wall Street analysts, ANL has a consensus that is bullish. The median price target is $9.00, with forecasts ranging from $9.00 to $9.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With ANL currently trading at $2.10, the median price forecast suggests a 328.6% upside. The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 328.6% upside, while Joseph Pantginis at HC Wainwright & Co. provides the most conservative target, suggesting a 328.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANL Analyst Consensus
ANL Price Target Range
Latest ANL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $9.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $9.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $0.00 |
| Oct 24, 2023 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $30.00 |
Stocks Similar to Adlai Nortye Ltd. - American Depositary Shares
The following stocks are similar to Adlai Nortye based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Adlai Nortye Ltd. - American Depositary Shares (ANL) Financial Data
Adlai Nortye Ltd. - American Depositary Shares has a market capitalization of $77.49M with a P/E ratio of -0.3x. The company generates $5.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -1,293.4% and return on equity of -132.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Adlai Nortye Ltd. - American Depositary Shares (ANL) Company Overview
About Adlai Nortye Ltd. - American Depositary Shares
Develops innovative cancer therapies.
The company operates as a clinical-stage biotechnology firm focusing on the discovery and development of cancer therapies. It generates revenue through the progression of its drug candidates through various clinical trial phases, aiming for regulatory approvals that can lead to commercial sales. As its lead product, AN2025, advances through Phase III trials, the company positions itself for potential licensing deals or partnerships with larger pharmaceutical companies.
Founded in 2004 and headquartered in Grand Cayman, the company is actively involved in multiple clinical trials targeting various types of cancer, leveraging innovative approaches such as phosphoinositide 3-kinase inhibition and PD-L1 modulation. Its pipeline includes several promising preclinical candidates that may diversify its product offerings in the oncology market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
127
CEO
Mr. Yang Lu
Country
Cayman Islands
IPO Year
N/A
Website
www.adlainortye.comAdlai Nortye Ltd. - American Depositary Shares (ANL) Latest News & Analysis
Adlai Nortye Ltd. Sponsored ADR (ANL) Loses -33.06% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
5 months agoAdlai Nortye Ltd. (ANL) is now considered technically oversold, indicating a potential exhaustion of heavy selling pressure.
ANL being technically oversold suggests a potential rebound, signaling a buying opportunity as selling pressure diminishes, which could lead to price recovery and increased investor interest.
Adlai Nortye Ltd. (NASDAQ: ANL) will present preliminary data on its cancer therapy AN0025 combined with dCRT for esophageal cancer at the ASCO Annual Meeting from May 31 to June 4, 2024.
Encouraging data on AN0025 could enhance Adlai Nortye's valuation and attract investment by signaling potential advancements in cancer treatment, impacting stock performance.
Adlai Nortye Ltd. (NASDAQ: ANL) has initiated a Phase II clinical trial, ARTEMIS, for its EP4 antagonist, palupiprant, in combination with chemoradiotherapy for rectal cancer treatment.
Adlai Nortye's Phase II trial for its cancer therapy could significantly impact its market value, signaling potential advancements in treatment and attracting investor interest in biotech innovation.
Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) performance will be compared to their sector's performance for the year, indicating their relative market standing.
Performance comparisons highlight relative strength or weakness, influencing investment decisions and stock valuations. Insights into sector trends can guide portfolio adjustments.
Adlai Nortye Ltd. (ANL) and Elevance Health (ELV) have shown performance metrics against their sector in 2023, indicating their relative market position.
The performance comparison of Adlai Nortye Ltd. and Elevance Health against their sector indicates market positioning, potential growth, and investment opportunities within their industries.
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
10 months agoAdlai Nortye Ltd. appointed Dr. Archie Tse as Head of Research & Development, effective March 29, 2024, reporting to CEO Carsten Lu. The company focuses on innovative cancer therapies.
Dr. Archie Tse's appointment as Head of R&D at Adlai Nortye could enhance the company's innovation pipeline, potentially leading to breakthroughs in cancer therapies and impacting stock performance.
Frequently Asked Questions About ANL Stock
What is Adlai Nortye Ltd. - American Depositary Shares's (ANL) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Adlai Nortye Ltd. - American Depositary Shares (ANL) has a median price target of $9.00. The highest price target is $9.00 and the lowest is $9.00.
Is ANL stock a good investment in 2025?
According to current analyst ratings, ANL has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ANL stock?
Wall Street analysts predict ANL stock could reach $9.00 in the next 12 months. This represents a 328.6% increase from the current price of $2.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Adlai Nortye Ltd. - American Depositary Shares's business model?
The company operates as a clinical-stage biotechnology firm focusing on the discovery and development of cancer therapies. It generates revenue through the progression of its drug candidates through various clinical trial phases, aiming for regulatory approvals that can lead to commercial sales. As its lead product, AN2025, advances through Phase III trials, the company positions itself for potential licensing deals or partnerships with larger pharmaceutical companies.
What is the highest forecasted price for ANL Adlai Nortye Ltd. - American Depositary Shares?
The highest price target for ANL is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 328.6% increase from the current price of $2.10.
What is the lowest forecasted price for ANL Adlai Nortye Ltd. - American Depositary Shares?
The lowest price target for ANL is $9.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 328.6% increase from the current price of $2.10.
What is the overall ANL consensus from analysts for Adlai Nortye Ltd. - American Depositary Shares?
The overall analyst consensus for ANL is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are ANL stock price projections?
Stock price projections, including those for Adlai Nortye Ltd. - American Depositary Shares, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
